A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• A diagnosis of GPP or EP prior to the screening visit.
• Candidate for phototherapy or systemic therapy.
Locations
Other Locations
Japan
St.Luke's International Hospital
RECRUITING
Chuo City
Fukuoka University Hospital
RECRUITING
Fukuoka
Kansai Medical University Hospital
RECRUITING
Hirakata
Saitama Medical University Hospital
RECRUITING
Iruma
Tokai University Hospital
RECRUITING
Isehara
Isesaki Municipal Hospital
RECRUITING
Isesaki
Teikyo University Hospital
RECRUITING
Itabashi-ku
Kimitsu Chuo Hospital
RECRUITING
Kisarazu
Hospital of the University of Occupational and Environmental Health, Japan
RECRUITING
Kitakyushu
Kobe University Hospital
RECRUITING
Kobe
University Hospital, Kyoto Prefectural University of Medicine
RECRUITING
Kyoto
The Jikei University Hospital
RECRUITING
Minato-ku
Nagoya City University Hospital
RECRUITING
Nagoya
Okayama University Hospital
RECRUITING
Okayama
Nippon Life Hospital
RECRUITING
Osaka
Osaka Metropolitan University Hospital
RECRUITING
Osaka
Tokyo Medical University Hospital
RECRUITING
Shinjuku-ku
Fujita Health University Hospital
RECRUITING
Toyoake
Mie University Hospital
RECRUITING
Tsu
Juntendo University Urayasu Hospital
RECRUITING
Urayasu
Contact Information
Primary
Takeda Contact
medinfoUS@takeda.com
+1-877-825-3327
Time Frame
Start Date: 2024-03-19
Estimated Completion Date: 2026-03-27
Participants
Target number of participants: 20
Treatments
Experimental: TAK-279 for Generalized Pustular Psoriasis
Participants with generalized pustular psoriasis will receive TAK-279 from Day 1 up to Week 52.
Experimental: TAK-279 for Erythrodermic Psoriasis
Participants with erythrodermic psoriasis will receive TAK-279 from Day 1 up to Week 52.
Related Therapeutic Areas
Sponsors
Leads: Takeda